Psoriatic arthritis takes several forms, with the asymmetric and symmetric kinds the most common. Learn more about types and treatments.

Rituximab is a chimeric human/mouse monoclonal anti-CD20 antibody approved for the treatment of rheumatoid arthritis (RA) refractory to anti-tumour necrosis factor (TNF) therapy.1 Rituximab seems to ...

In order to measure disease activity, progression, and change with therapy in psoriatic arthritis (PsA), it is important to use accurate, reliable, and feasible outcome measures that can ideally be ...

A global comparison of psoriatic arthritis guidelines reveals differences in treatment sequencing and domain-specific strategies, with all emphasizing treat-to-target goals and comorbidity management.

A large cohort study of patients with psoriasis using wearable devices finds more exercise is associated with a lower risk ...

Patients with psoriatic arthritis who meet clinical criteria for minimal disease activity also tend to report good disease ...

Significant gaps in arthritis subtype awareness among US adults underscore the need for improved health literacy and more ...

Medically reviewed by David Ozeri, MD Psoriatic arthritis and rheumatoid arthritis (RA) are both forms of inflammatory arthritis. They each cause chronic swelling, stiffness, and pain in your joints.

While medication is the best way to treat psoriatic arthritis, adding complementary therapies to your treatment plan may help ease joint symptoms.

Incidences of malignant neoplasms were low and stable with long-term ixekizumab treatment for people with psoriatic disease ...

When psoriatic arthritis symptoms are under control, you may be tempted to stop taking medication. Here’s why that’s a bad idea.

This review discusses the features of oligoarticular, polyarticular, systemic, and psoriatic JIA and enthesitis-related arthritis, as well as advances in treatment for these conditions.